Heartflow, Inc. (HTFL) stock
HTFLNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30547% above fair value
$59.92+0.82 (+1.39%)
Close on Nov 12, 2026Market cap $5.21BP/E –Yield –
Heartflow r&d expenses
Research and development expenses are spending on new products and technology.
Heartflow's R&D Expenses for the twelve months ending Sep 30, 2026 was $96.03M, up 64.1% year over year. For fiscal 2025 it was $64.92M, up 49.2% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.92M | +49.2% |
| FY2024 | Dec 31, 2024 | $43.52M | +21.4% |
| FY2023 | Dec 31, 2023 | $35.85M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $29.49M | +70.5% |
| Q2 FY2026 | Jun 30, 2026 | $26.26M | +74.7% |
| Q1 FY2026 | Mar 31, 2026 | $21.62M | +55.3% |
| Q4 FY2025 | Dec 31, 2025 | $18.67M | +52.0% |
| Q3 FY2025 | Sep 30, 2025 | $17.30M | +45.8% |
| Q2 FY2025 | Jun 30, 2025 | $15.03M | +51.3% |
| Q1 FY2025 | Mar 31, 2025 | $13.92M | – |
| Q4 FY2024 | Dec 31, 2024 | $12.28M | – |
| Q3 FY2024 | Sep 30, 2024 | $11.86M | – |
| Q2 FY2024 | Jun 30, 2024 | $9.93M | – |
See a number that looks wrong?